THANK YOU Philanthropy fuels innovation at the University of Colorado Anschutz Medical Campus, and your giving is transforming the treatment options available to individuals with urologic cancers. New and innovative treatments are changing lives and improving outcomes. We are creating a future in which a cancer diagnosis is no longer a life-altering prospect — a future in which targeted therapies are effective the first time, giving the gift of time to our patients. Thank you for joining us on this journey.
Revolutionizing medical care for cancer
Researchers at the CU Anschutz Medical Campus are dedicated to rewriting the rules of medicine. Under the umbrella of personalized medicine, our treatment options are becoming more precise and effective by harnessing genetic data. Because of the dedication of our physician-researchers, the medicine of tomorrow will far exceed our current expectations. Momentum is on our side, and we have the top talent and stateof-the-art facilities to stake our claim at the forefront of innovation. This
PAUL MARONI, MD
innovation translates into improved patient outcomes.
New treatment options for prostate cancer
Dr. Paul Maroni’s research interests include pioneering new treatment options for patients with urologic cancers and developing new, less-invasive surgery techniques for patients with prostate cancer. Along with his research partners, Dr. Maroni has developed specialized robotic surgery techniques to
IN 7 MEN minimize the recovery time1associated with WILL surgeriesBE that DIAGNOSED would otherwise
WITH
PROSTATE CANCER DURING HIStimes LIFETIME be fairly invasive. These new treatment options are speeding recovery and getting people back to healthy lives quicker than before.
161,000+
Collaborating throughout the University of Colorado Anschutz Medical Campus
Dr. Maroni collaborates with several researchers at the CU Anschutz Medical
NEW
Campus including Rajesh Agarwal, PhD, in the CU Skaggs School of
MD from University of Illinois College of Medicine Joined CU in 2007 as Associate Professor of
CASES OF PROSTATE Pharmacy and Pharmaceutical Sciences. Dr. Agarwal is a national leader CANCER IN 2017
Surgery
seed extract, phytic acid and bitter melon and the role they may play in
Doc recognition in 5280
researching the molecules inside natural products such as milk thistle, grape fighting cancer.
PROSTATE
CANCER IS THE
3RD
2014, 2015 and 2016 Top
LEADING CAUSE OF CANCER DEATH IN AMERICAN MEN
Together, Drs. Maroni and Agarwal are in the beginning stages of a clinical trial at the CU Cancer Center to test the effectiveness of grape seed extract in slowing the rise of prostate-specific antigen (PSA). This trial will enroll 40 men with asymptomatic and non-metastatic prostate cancer with rising PSA, who will take grape seed extract orally twice per day. These men would otherwise be on a watch-and-wait protocol, and will be evaluated every six weeks for a year to measure the progress of their cancer.
1 IN 7 MEN WILL BE DIAGNOSED WITH
PROSTATE CANCER LIFETIME Drs. Maroni and AgarwalDURING hope thatHIS PSAs will not rise as quickly as in the past for patients taking the grape seek extract, slowing the disease progression and allowing more patients to live with the disease but not die from it.
161,000+ NEW
CASES OF PROSTATE CANCER IN 2017
1 IN 7 MEN WILL BE DIAGNOSED WITH PROSTATE CANCER DURING HIS LIFETIME
The future of medicine is personalized
CU Anschutz is leading the way in personalized medicine through the Colorado Center for Personalized
161,000+
3RD
Medicine. By understanding genetics, physicians will have access to the most personal information about
OFbigCANCER STATE your health and develop aLEADING plan specificallyCAUSE for you. Using data and the latest genetic knowledge,
IN AMERICAN MEN IS THEyour doctor will be able toDEATH go from a drug to your drug, making treatment more effective from the very
NEW
CASES OF cancer PROSTATE beginning. This work is revolutionizing medicine and impacting all areas of health from to multiple sclerosis, mental health and more.
CANCER IN 2017
The innovative research happening on the CU Anschutz Medical Campus is made possible by generous philanthropic partners like the Writer Foundation. Thank you for your continued confidence in our institution
PROSTATE
and for helping us create the future of medicine.
CANCER IS THE
3RD
LEADING CAUSE OF CA DEATH IN AMERICAN M
Angela DellaSalle, Senior Director of Development angela.dellasalle@ucdenver.edu | 303-724-6334 (office) | 303-523-7190 (cell) 13001 East 17th Place, Suite WG112 | Aurora, CO 80045 supportcuanschutz.ucdenver.edu